Study Comparing Two Treatment Combinations for Newly Diagnosed Multiple Myeloma

Inclusion Criteria

• Must have been newly diagnosed with multiple myeloma and need treatment.
• No previous chemotherapy for multiple myeloma, and limited prior steroid use is allowed.
• Both patients who are candidates for a stem cell transplant and those who are not can participate, but transplant candidates must agree to delay the transplant.
• Must have symptomatic multiple myeloma as per specific medical criteria.
• Must have a certain level of cancer cells in the bone marrow or a biopsy-proven plasmacytoma.
• Must have measurable disease based on specific protein levels in the blood or urine.
• Must provide a bone marrow sample for study purposes.
• Must be 18 years or older.
• Must have a good performance status, meaning they are fully active or have some restrictions but can still perform light work.
• Must have adequate liver function and specific blood cell counts.
• Must have good kidney function.
• Women of childbearing potential must have two negative pregnancy tests before starting treatment and agree to use effective contraception.
• Men must agree to use condoms during sexual activity and for a period after the study.
• Must agree to participate in the Revlimid REMS® program and comply with its requirements.
• Must agree to pregnancy prevention and counseling.
• Must provide written informed consent to participate.

Exclusion Criteria

• Patients who are frail and not candidates for a transplant.
• Patients with certain types of multiple myeloma that do not produce enough protein to measure.
• Patients with specific syndromes or other types of blood cancers.
• Patients who have had recent extensive radiation or immunotherapy.
• Patients who have participated in another investigational study recently.
• Patients with progressive disease as per specific criteria.
• Patients who cannot tolerate the study medications.
• Patients with significant nerve damage or severe diarrhea.
• Patients with central nervous system involvement.
• Patients who cannot take blood clot prevention medication.
• Patients with recent severe heart conditions or uncontrolled heart issues.
• Pregnant or breastfeeding women.
• Patients who have had major surgery recently.
• Patients with recent heart attacks or severe heart failure.
• Patients with a history of blood clots or severe lung conditions.
• Patients with uncontrolled diabetes or infections.
• Patients with active viral infections like HIV or hepatitis.
• Patients with other cancers within the past three years, except for certain skin or prostate cancers.
• Patients with any medical condition that might interfere with the study or their ability to consent.